FINANCIAL HIGHLIGHTS
- Significant reduction in operating costs in Q3
-
Cash position on
30 September 2021 (SEK 23.5 million) still expected to cover the Tourette study
R&D HIGHLIGHTS
- TOURETTE SYNDROME
Following an administrative delay from
- OCD
This quarter we have continued internal discussions on how best to finance a clinical study in OCD. This follows the granting of a US patent for Sepranolone for the treatment of Tourette, Obsessive-compulsive Disorder (OCD) and pathological gambling in June (valid until 2038).
To read the Report in full please visit: https://asarinapharma.com/investors/financial-reports/
For further information, please contact:
Peter Nordkild, CEO
Phone: +45 25 47 16 46
E-mail: peter.nordkild@asarinapharma.com
Jakob Dynnes Hansen, CFO
Phone: +45 5132 3698
E-mail: jakob.dynnes@asarinapharma.com
Certified Adviser
Phone: +46 8-463 83 00
Mail: certifiedadviser@penser.se
ABOUT
We are a Swedish biotech company developing Sepranolone for allopregnanolone-induced stress- and compulsivity-driven disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of safe, efficacious drugs for neurological conditions from Tourette syndrome to Obsessive compulsive disorder that still lack safe, efficacious pharmaceutical treatments.
The information above was provided by the CEO of
https://news.cision.com/asarina-pharma/r/asarina-pharma-ab--publ--q3-report-2021-released,c3460275
https://mb.cision.com/Main/17069/3460275/1501299.pdf
https://mb.cision.com/Public/17069/3460275/9cabaa609518d368.pdf
(c) 2021 Cision. All rights reserved., source